Nature Clinical Practice Oncology Nature Clinical Practice Oncology provides oncologists with authoritative and timely interpretations of key developments in the field, translating the latest findings into clinical practice. http://www.nature.com/ncponc/current_issue/ Nature Publishing Group en © Nature Publishing Group Nature Clinical Practice Oncology 1743-4254 1743-4262 © Nature Publishing Group permissions@nature.com Nature Clinical Practice Oncology http://www.nature.com/includes/rj_globnavimages/ncponc_logo.gif http://www.nature.com/ncponc/ Radiation therapy improves survival in patients with pancreatic adenocarcinoma http://dx.doi.org/10.1038/ncponc1176 Radiation therapy improves survival in patients with pancreatic adenocarcinoma

Nature Clinical Practice Oncology. doi:10.1038/ncponc1176

Authors: Felix Y Feng & Edgar Ben-Josef

]]> Radiation therapy improves survival in patients with pancreatic adenocarcinoma Felix Y Feng Edgar Ben-Josef doi:10.1038/ncponc1176 Nature Clinical Practice Oncology 2008-07-01 Nature Clinical Practice Oncology 2008-07-01 Practice Point Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer http://dx.doi.org/10.1038/ncponc1163 Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer

Nature Clinical Practice Oncology. doi:10.1038/ncponc1163

Authors: Lisa J Hazard, Jonathan D Tward & Dennis C Shrieve

]]> Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer Lisa J Hazard Jonathan D Tward Dennis C Shrieve doi:10.1038/ncponc1163 Nature Clinical Practice Oncology 2008-06-24 Nature Clinical Practice Oncology 2008-06-24 Practice Point The CCR9–CCL25 axis mediates melanoma metastasis to the small intestine http://dx.doi.org/10.1038/ncponc1174 The CCR9–CCL25 axis mediates melanoma metastasis to the small intestine

Nature Clinical Practice Oncology. doi:10.1038/ncponc1174

Author: Joost van den Oord

]]> The CCR9–CCL25 axis mediates melanoma metastasis to the small intestine Joost van den Oord doi:10.1038/ncponc1174 Nature Clinical Practice Oncology 2008-06-24 Nature Clinical Practice Oncology 2008-06-24 Practice Point Bevacizumab plus interferon α in patients with metastatic renal cell carcinoma http://dx.doi.org/10.1038/ncponc1162 Bevacizumab plus interferon α in patients with metastatic renal cell carcinoma

Nature Clinical Practice Oncology. doi:10.1038/ncponc1162

Authors: Przemyslaw Twardowski & Robert A Figlin

]]> Bevacizumab plus interferon α in patients with metastatic renal cell carcinoma Przemyslaw Twardowski Robert A Figlin doi:10.1038/ncponc1162 Nature Clinical Practice Oncology 2008-06-17 Nature Clinical Practice Oncology 2008-06-17 Practice Point Does computer-aided detection increase the accuracy of interpretation of mammograms? http://dx.doi.org/10.1038/ncponc0963 Does computer-aided detection increase the accuracy of interpretation of mammograms?

Nature Clinical Practice Oncology. doi:10.1038/ncponc0963

Author: Berkman Sahiner

]]> Does computer-aided detection increase the accuracy of interpretation of mammograms? Berkman Sahiner doi:10.1038/ncponc0963 Nature Clinical Practice Oncology 2007-10-02 Nature Clinical Practice Oncology 2007-10-02 Practice Point Chemotherapy for osteosarcoma with high-dose methotrexate is effective and outpatient therapy is now possible http://dx.doi.org/10.1038/ncponc0953 Chemotherapy for osteosarcoma with high-dose methotrexate is effective and outpatient therapy is now possible

Nature Clinical Practice Oncology. doi:10.1038/ncponc0953

Author: Pete Anderson

]]> Chemotherapy for osteosarcoma with high-dose methotrexate is effective and outpatient therapy is now possible Pete Anderson doi:10.1038/ncponc0953 Nature Clinical Practice Oncology 2007-09-18 Nature Clinical Practice Oncology 2007-09-18 Practice Point Does adjuvant radiotherapy increase survival in patients with Merkel cell carcinoma of the skin? http://dx.doi.org/10.1038/ncponc0952 Does adjuvant radiotherapy increase survival in patients with Merkel cell carcinoma of the skin?

Nature Clinical Practice Oncology. doi:10.1038/ncponc0952

Author: Marc Bischof

]]> Does adjuvant radiotherapy increase survival in patients with Merkel cell carcinoma of the skin? Marc Bischof doi:10.1038/ncponc0952 Nature Clinical Practice Oncology 2007-09-18 Nature Clinical Practice Oncology 2007-09-18 Practice Point Aromatase inhibitors and tamoxifen: where do we go from here? http://dx.doi.org/10.1038/ncponc0955 Aromatase inhibitors and tamoxifen: where do we go from here?

Nature Clinical Practice Oncology. doi:10.1038/ncponc0955

Authors: Matthew P Goetz & Charles L Loprinzi

]]> Aromatase inhibitors and tamoxifen: where do we go from here? Matthew P Goetz Charles L Loprinzi doi:10.1038/ncponc0955 Nature Clinical Practice Oncology 2007-09-11 Nature Clinical Practice Oncology 2007-09-11 Practice Point The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer http://dx.doi.org/10.1038/ncponc0936 The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer

Nature Clinical Practice Oncology. doi:10.1038/ncponc0936

Author: Maurie Markman

]]> The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer Maurie Markman doi:10.1038/ncponc0936 Nature Clinical Practice Oncology 2007-09-04 Nature Clinical Practice Oncology 2007-09-04 Practice Point Who should receive myeloablative therapy for diffuse large B-cell lymphoma? http://dx.doi.org/10.1038/ncponc1175 Over half of all newly-diagnosed diffuse large B-cell lymphoma patients can be cured with first line treatment based on the combination of rituximab with anthracycline-based chemotherapy regimens. The authors of this Viewpoint discuss the use of high-dose therapy and autologous hematopoietic stem cell support in patients with DLBCL who have relapsed or are refractory to first line treatment. Who should receive myeloablative therapy for diffuse large B-cell lymphoma?

Nature Clinical Practice Oncology. doi:10.1038/ncponc1175

Authors: Luciano Wannesson & Emanuele Zucca

]]> Who should receive myeloablative therapy for diffuse large B-cell lymphoma? Luciano Wannesson Emanuele Zucca doi:10.1038/ncponc1175 Nature Clinical Practice Oncology 2008-07-08 Nature Clinical Practice Oncology 2008-07-08 Viewpoint Stereotactic radiotherapy for stage I non-small-cell lung cancer—the triumph of technology over biology? http://dx.doi.org/10.1038/ncponc0954 Should patients with stage I non-small-cell lung cancer who are unsuitable for surgery receive hypofractionated stereotactic radiotherapy? In the rush to implement new technology, there could be a danger of overlooking refinements important to ensure safety, according to the author of this Viewpoint. Stereotactic radiotherapy for stage I non-small-cell lung cancer—the triumph of technology over biology?

Nature Clinical Practice Oncology. doi:10.1038/ncponc0954

Authors: David Ball & H Rodney Withers

]]> Stereotactic radiotherapy for stage I non-small-cell lung cancer—the triumph of technology over biology? David Ball H Rodney Withers doi:10.1038/ncponc0954 Nature Clinical Practice Oncology 2007-09-11 Nature Clinical Practice Oncology 2007-09-11 Viewpoint Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC http://dx.doi.org/10.1038/ncponc1173 Mammalian target of rapamycin (mTOR) is an important and clinically relevant therapeutic target. Temsirolimus has significantly improved overall survival rates in patients with advanced renal cell carcinoma, thereby validating the importance of mTOR in the natural history of this disease. This Review discusses the clinical development of temsirolimus, its novel mechanism of action, and the investigational strategies for targeting mTOR in other tumor types. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC

Nature Clinical Practice Oncology. doi:10.1038/ncponc1173

Author: Robert A Figlin

]]> Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC Robert A Figlin doi:10.1038/ncponc1173 Nature Clinical Practice Oncology 2008-07-08 Nature Clinical Practice Oncology 2008-07-08 Review The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 http://dx.doi.org/10.1038/ncponc1179 Estrogen-deprivation strategies with aromatase inhibitors are superior to tamoxifen in the adjuvant, neoadjuvant and advanced breast-cancer settings in postmenopausal patients. Short-term hormonal resistance especially in the HER2-positive patient population, however, is a significant issue with these endocrine agents. The authors discuss the progress made in our understanding of resistance to endocrine therapy, and provide insights regarding the management of patients with hormone receptor-positive/HER2-positive advanced breast cancer. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2

Nature Clinical Practice Oncology. doi:10.1038/ncponc1179

Authors: Aleix Prat & José Baselga

]]> The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 Aleix Prat José Baselga doi:10.1038/ncponc1179 Nature Clinical Practice Oncology 2008-07-08 Nature Clinical Practice Oncology 2008-07-08 Review Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer http://dx.doi.org/10.1038/ncponc1156 There are few treatment options for patients with metastatic HER2-positive breast cancer who are unresponsive to trastuzumab. The combination of lapatinib and capecitabine significantly prolongs time to disease progression in women previously treated with chemotherapy and trastuzumab for HER2-positive advanced disease. The rationale for using this combination and the promising activity of lapatinib in early trials of inflammatory breast cancer is highlighted. Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer

Nature Clinical Practice Oncology. doi:10.1038/ncponc1156

Authors: David A Cameron & Steven Stein

]]> Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer David A Cameron Steven Stein doi:10.1038/ncponc1156 Nature Clinical Practice Oncology 2008-07-01 Nature Clinical Practice Oncology 2008-07-01 Review Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications http://dx.doi.org/10.1038/ncponc1161 It is unlikely that tumors are entirely dependent on only one abnormally activated signaling pathway and, consequently, treatment with an agent interfering with a single target may be insufficient. This Review discusses the experimental and early-stage clinical evidence to support the relevance of EGFR-dependent and VEGF-dependent pathways, their functional links and the implications of acquired resistance to targeted therapies. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications

Nature Clinical Practice Oncology. doi:10.1038/ncponc1161

Authors: Giampaolo Tortora, Fortunato Ciardiello & Giampietro Gasparini

]]> Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications Giampaolo Tortora Fortunato Ciardiello Giampietro Gasparini doi:10.1038/ncponc1161 Nature Clinical Practice Oncology 2008-07-01 Nature Clinical Practice Oncology 2008-07-01 Review Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties http://dx.doi.org/10.1038/ncponc1159 There is a paucity of phase III data comparing chemoradiation with radiation alone for treating invasive bladder cancer; however, an ongoing Australian trial is attempting to address this lack of data. Strategies that combine systemic chemotherapy and radiotherapy have been explored and have yielded better local control than either modality alone. The role of systemic chemotherapy and the controversies surrounding the use of radical surgery versus chemoradiation are discussed. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties

Nature Clinical Practice Oncology. doi:10.1038/ncponc1159

Authors: Toni K Choueiri & Derek Raghavan

]]> Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties Toni K Choueiri Derek Raghavan doi:10.1038/ncponc1159 Nature Clinical Practice Oncology 2008-06-24 Nature Clinical Practice Oncology 2008-06-24 Review Mechanisms of Disease: temozolomide and glioblastoma—look to the future http://dx.doi.org/10.1038/ncponc1155 Until recently, the standard of care for the treatment of glioblastoma involved surgical resection followed by radiation therapy with or without nitrosourea-based chemotherapy. In 2005, a large trial established adjuvant temozolomide chemotherapy and radiotherapy as a new standard therapy. This Review summarizes new developments in the treatment of glioblastoma and speculates on possible future treatment strategies for managing this aggressive cancer. Mechanisms of Disease: temozolomide and glioblastoma—look to the future

Nature Clinical Practice Oncology. doi:10.1038/ncponc1155

Authors: Maciej M Mrugala & Marc C Chamberlain

]]> Mechanisms of Disease: temozolomide and glioblastoma—look to the future Maciej M Mrugala Marc C Chamberlain doi:10.1038/ncponc1155 Nature Clinical Practice Oncology 2008-06-10 Nature Clinical Practice Oncology 2008-06-10 Review Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer http://dx.doi.org/10.1038/ncponc1137 Many drugs are used to treat colorectal cancer but there is little information about how predictive factors can be used to improve treatment response and reduce toxic effects related to anticancer treatment. The authors of this Review analyse the main data in this investigation field, and highlight the most important predictive factors that relate to toxic effects in patients with colorectal cancer who are treated with anticancer chemotherapy, both in adjuvant and in advanced setting. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer

Nature Clinical Practice Oncology. doi:10.1038/ncponc1137

Authors: Bruno Vincenzi, Gaia Schiavon, Francesco Pantano, Daniele Santini & Giuseppe Tonini

]]> Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer Bruno Vincenzi Gaia Schiavon Francesco Pantano Daniele Santini Giuseppe Tonini doi:10.1038/ncponc1137 Nature Clinical Practice Oncology 2008-06-10 Nature Clinical Practice Oncology 2008-06-10 Review Do stress-related psychosocial factors contribute to cancer incidence and survival? http://dx.doi.org/10.1038/ncponc1134 Although many studies have investigated the associations between stress-related psychosocial factors and cancer outcomes, the results have been inconclusive. The authors of this Review use meta-analytical methods from 165 studies to determine if there is an association, and discuss the results indicating that stress-related psychosocial factors have an adverse effect on cancer incidence and survival. Do stress-related psychosocial factors contribute to cancer incidence and survival?

Nature Clinical Practice Oncology. doi:10.1038/ncponc1134

Authors: Yoichi Chida, Mark Hamer, Jane Wardle & Andrew Steptoe

]]> Do stress-related psychosocial factors contribute to cancer incidence and survival? Yoichi Chida Mark Hamer Jane Wardle Andrew Steptoe doi:10.1038/ncponc1134 Nature Clinical Practice Oncology 2008-05-20 Nature Clinical Practice Oncology 2008-05-20 Review Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy http://dx.doi.org/10.1038/ncponc1157 The tumor suppressor syndrome neurofibromatosis type 2 (NF2) is transmitted in an autosomal dominant fashion. Plotkin et al. report the case of a 48-year-old man who was diagnosed with progressive NF2-related vestibular schwannomas and received erlotinib therapy, which resulted in improved audiologic and radiographic responses. The authors discuss the potential effectiveness of targeted therapies for progressive vestibular schwannoma in NF2 patients. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy

Nature Clinical Practice Oncology. doi:10.1038/ncponc1157

Authors: Scott R Plotkin, Marybeth A Singh, Caroline C O'Donnell, Gordon J Harris, Andrea I McClatchey & Chris Halpin

]]> Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy Scott R Plotkin Marybeth A Singh Caroline C O'Donnell Gordon J Harris Andrea I McClatchey Chris Halpin doi:10.1038/ncponc1157 Nature Clinical Practice Oncology 2008-06-17 Nature Clinical Practice Oncology 2008-06-17 Case Study